Compare ARAY & CSBR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARAY | CSBR |
|---|---|---|
| Founded | 1990 | 1985 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 68.6M | 82.7M |
| IPO Year | 2006 | 2015 |
| Metric | ARAY | CSBR |
|---|---|---|
| Price | $0.41 | $5.90 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $3.50 | ★ $12.00 |
| AVG Volume (30 Days) | ★ 887.9K | 5.0K |
| Earning Date | 05-05-2026 | 03-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 87.50 | ★ 161.11 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $2,900,000.00 |
| Revenue This Year | N/A | $4.84 |
| Revenue Next Year | $4.58 | $11.51 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.46 | $5.59 |
| 52 Week High | $2.10 | $10.25 |
| Indicator | ARAY | CSBR |
|---|---|---|
| Relative Strength Index (RSI) | 22.29 | 39.75 |
| Support Level | N/A | $5.59 |
| Resistance Level | $0.63 | $6.96 |
| Average True Range (ATR) | 0.04 | 0.18 |
| MACD | -0.00 | 0.02 |
| Stochastic Oscillator | 0.00 | 13.21 |
Accuray Inc is a radiation oncology company that develops, manufactures, sells and supports precise, treatment solutions which set the standard of radiation therapy care with the objective of helping patients live lives. The company's technology, The CyberKnife, is used to treat multiple types of cancer and tumors throughout the body. The CyberKnife Systems automatically track, detect and correct for a tumor and patient movement in real-time during the procedure, enabling delivery of precise, high dose radiation with sub-millimetre accuracy while patients breathe normally, without manual user intervention.
Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies. The company's revenue is majorly derived from research services.